Jiří Piťha

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis

Tomáš Kozák, Eva Havrdová, Jiří Piťha et al. · Bone Marrow Transplantation · 2000 · 109 citations

High-dose Immunosuppressive Therapy, Autoimmune Disease, Immunosuppressive Therapy +11

MuSK autoantibodies in myasthenia gravis detected by cell based assay — A multinational study

Anastasios Tsonis, Paraskevi Zisimopoulou, Konstantinos Lazaridis et al. · Journal of Neuroimmunology · 2015 · 79 citations · Full text

Autoimmune Disease, Musk Autoantibodies, Immunology +7

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text